Project Details
Projekt
Role of FBXO41 in maintaining the undifferentiated state in acute myeloid leukemia (A01)
Subject Area
Hematology, Oncology
Term
since 2024
Project identifier
Deutsche Forschungsgemeinschaft (DFG) - Project number 514894665
Acute myeloid leukemia (AML) has a poor prognosis with a 5-year survival rate of only 25 percent, despite substantial insights into the genetic landscape of the disease. Vulnerabilities on the post-translational level may thus be promising. Starting from CRISPR/Cas9-based screening and cross validation in a large AML patient cohort, we specified FBXO41 as a promising candidate that promotes the undifferentiated state in AML. We will therefore aim to identify the substrate(s) of FBXO41 and the regulatory network thereof to unravel its oncogenic mechanism and pave the way for FBXO41 based targeting approaches in AML.
DFG Programme
CRC/Transregios
Applicant Institution
Technische Universität München (TUM)
Project Head
Professor Dr. Florian Bassermann
